Lecanemab reduces toxic amyloid-β protofibrils, slowing Alzheimer’s disease progression and supporting personalised treatment ...

The gene mutation was isolated in a family in northern Italy where under half of the relations developed the disease. View on ...

The Community Foundation for Brevard recently awarded $100,000 to Florida Institute of Technology’s Shaohua Xu, Ph.D., to ...

The disease afflicts nearly seven million Americans, about one in every nine people over the age of 65, making it a leading ...

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...

Three common heart conditions—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and a higher risk of dementia, according to a new scientific ...

Across Iowa, 11% of people, 65 or older, have Alzheimer's. That number is even higher in rural counties. Here's how you can get support, with a virtual forum.

Gordon is survived by his beloved family, including sister Shirley O’Connor; nephew Mark Sardzinski; nieces Aimee Cormier, Laura Dos Santos, and Sarah Willett, their families, and many friends – all ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to advance its Alzheimer's candidate VG-3927 into a Phase 2 ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.